Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3240-3246

  De Graan, Anne Joy M ^a   Teunissen, Sebastiaan F ^c   De Vos, Filip Y F L ^a   Loos, Walter J ^a   Van Schaik, Ron H N ^a   De Jongh, Felix E ^b   De Vos, Aad I ^d   Van Alphen, Robbert J ^e   Van Der Holt, Bronno ^a   Verweij, Jaap ^a   Seynaeve, Caroline ^a   Beijnen, Jos H ^c   Mathijssen, Ron H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d Admiraal de Ruyter Hospital   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROMETHORPHAN; DRUG METABOLITE; ENDOXIFEN; PAROXETINE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 80052009180     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.9839     Document Type: Article

References (47)

1. Schroth W., Antoniadou L., Fritz P., et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007 (Pubitemid 350232249)
2. Goetz M.P., Rae J.M., Suman V.J., et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005
3. Stearns V., Johnson M.D., Rae J.M., et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003 (Pubitemid 38008898)
4. Jin Y., Desta Z., Stearns V., et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005
5. Borges S., Desta Z., Jin Y., et al: Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50:450-458, 2010
6. Desta Z., Flockhart D.A.: Germline pharmacogenetics of tamoxifen response: Have we learned enough? J Clin Oncol 25:5147-5149, 2007 (Pubitemid 350232242)
7. Bonanni B., Macis D., Maisonneuve P., et al: Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: Data from the Italian Tamoxifen Trial. J Clin Oncol 24:3708-3709, 2006; author reply 3709
8. Goetz M.P., Kamal A., Ames M.M.: Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 83: 160-166, 2008
9. Lammers L.A., Mathijssen R.H., Van Gelder T., et al: The impact of CYP2D6- Predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 103:765- 771, 2010
10. Coezy E., Borgna J.L., Rochefort H.: Tamoxifen and metabolites in MCF7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317-323, 1982 (Pubitemid 12207285)
11. Sideras K., Ingle J.N., Ames M.M., et al: Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28:2768-2776, 2010
12. Goetz M.P., Knox S.K., Suman V.J., et al: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121, 2007 (Pubitemid 47555336)
13. Schroth W., Hamann U., Fasching P.A., et al: CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification. Clin Cancer Res 16:4468-4477, 2010
14. Bijl M.J., Van Schaik R.H., Lammers L.A., et al: The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 118:125-130, 2009
15. Schroth W., Goetz M.P., Hamann U., et al: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436, 2009
16. Newman W.G., Hadfield K.D., Latif A., et al: Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 14:5913-5918, 2008
17. Kiyotani K., Mushiroda T., Imamura C.K., et al: Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287-1293, 2010
18. Thompson A.M., Johnson A., Quinlan P., et al: Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125:279-287, 2011
19. Nowell S.A., Ahn J., Rae J.M., et al: Association of genetic variation in tamoxifen- Metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258, 2005 (Pubitemid 40903087)
20. Wegman P., Elingarami S., Carstensen J., et al: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7, 2007
21. Okishiro M., Taguchi T., Jin Kim S., et al: Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 115:952-961, 2009
22. Ramón y Cajal T., Altés A., Paré L., et al: Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 119:33-38, 2010
23. Seruga B., Amir E.: Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: Results of a meta- Analysis. Breast Cancer Res Treat 122:609-617, 2010
24. Abraham J.E., Maranian M.J., Driver K.E., et al: CYP2D6 gene variants: Association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12: R64, 2010
25. Wegman P., Vainikka L., Stål O., et al: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7:R284-R290, 2005
26. Leyland-Jones B., Regan M.M., Bouzyk M., et al: Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 Trial. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-12, 2010 (abstr S1-8)
27. Rae J.M., Drury S., Hayes D.F., et al: Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC Trial. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-12, 2010 (abstr S1-7)
28. Lash T.L., Cronin-Fenton D., Ahern T.P., et al: CYP2D6 inhibition and breast cancer recurrence in a population- Based study in Denmark. J Natl Cancer Inst 103:489-500, 2011
29. Kelly C.M., Juurlink D.N., Gomes T., et al: Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. BMJ 340:c693, 2010
30. Aubert R.E., Stanek E.J., Yao J., et al: Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 27:9s, 2009 (suppl; abstr CRA508)
31. Brauch H., Mürdter T.E., Eichelbaum M., et al: Pharmacogenomics of tamoxifen therapy. Clin Chem 55:1770-1782, 2009
32. Hisaka A., Ohno Y., Yamamoto T., et al: Prediction of pharmacokinetic drug- Drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther 125:230-248, 2010
33. Mathijssen R.H., Van Schaik R.H.: Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment. Eur J Cancer 42:141-148, 2006 (Pubitemid 43083482)
34. Yu A., Haining R.L.: Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: Can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514-1520, 2001 (Pubitemid 33000701)
35. Teunissen S.F., Rosing H., Koornstra R.H., et al: Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:2519-2529, 2009
36. Loos W.J., De Graan A.J., De Bruijn P., et al: Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3- Methoxymorphinan and 3- Methoxymorphinan and 3Hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple- Methoxymorphinan and 3Hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem tripleQuadruple mass spectrometry. J Pharm Biomed Anal 54:387-394, 2011
37. Wegman P.P., Wingren S.: CYP2D6 variants and the prediction of tamoxifen response in randomized patients: Author response. Breast Cancer Res 7:E7, 2005
38. Van der Bol J.M., Mathijssen R.H., Creemers G.J., et al: A CYP3A4 phenotype- Based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 16:736-742, 2010
39. Mathijssen R.H., De Jong F.A., Van Schaik R.H., et al: Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592, 2004
40. Ducharme J., Abdullah S., Wainer I.W.: Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678:113-128, 1996 (Pubitemid 26114747)
41. Jones D.R., Gorski J.C., Haehner B.D., et al: Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N- Demethylation. Clin Pharmacol Ther 60:374-384, 1996 (Pubitemid 26355999)
42. Kawashima Y., Hagiwara M., Inoue Y., et al: Evaluation of dextromethorphan N- Demethylation activity as a biomarker for cytochrome P450 3A activity in man. Pharmacol Toxicol 90:82-88, 2002 (Pubitemid 34246173)
43. Samer C.F., Daali Y., Wagner M., et al: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 160:907-918, 2010
44. Dumond J.B., Vourvahis M., Rezk N.L., et al: A phenotype- Genotype approach to predicting CYP450 and P- Genotype approach to predicting CYP450 and PGlycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 87:735-742, 2010
45. Xu X., Liu H.Y., Liu L., et al: The influence of a newly developed quinolone: Antofloxacin, on CYP activity in rats. Eur J Drug Metab Pharmacokinet 33:1-7, 2008
46. Funck-Brentano C, Boëlle PY, Verstuyft C, et al: Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: Sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 61:821-829, 2005
47. Lin Y.S., Lockwood G.F., Graham M.A., et al: In- Vivo phenotyping for CYP3A by a single- Vivo phenotyping for CYP3A by a singlePoint determination of midazolam plasma concentration. Pharmacogenetics 11:781-791, 2001 (Pubitemid 33151513)